Comparison between clevidipine and nicardipine in cerebrovascular diseases: A systematic review and meta-analysis

[1]  J. Mocco,et al.  2022 Guideline for the Management of Patients With Spontaneous Intracerebral Hemorrhage: A Guideline From the American Heart Association/American Stroke Association. , 2022, Stroke.

[2]  J. Breslin,et al.  Comparison of Clevidipine and Nicardipine for Acute Blood Pressure Reduction in Hemorrhagic Stroke , 2021, Neurocritical Care.

[3]  Bethany E Martini,et al.  Comparison of premade clevidipine and pharmacy-prepared nicardipine in time to goal systolic blood pressure in acute cerebrovascular accident. , 2021, American Journal of Health-System Pharmacy.

[4]  R. Steele,et al.  Estimating the sample mean and standard deviation from commonly reported quantiles in meta-analysis , 2019, Statistical methods in medical research.

[5]  Karishma Chari,et al.  National Hospital Care Survey Demonstration Projects: Stroke Inpatient Hospitalizations. , 2019, National health statistics reports.

[6]  Breck A. Jones,et al.  Comparison of Nicardipine with Clevidipine in the Management of Hypertension in Acute Cerebrovascular Diseases. , 2018, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[7]  W. Powers,et al.  2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association , 2018, Stroke.

[8]  Kiwon Lee,et al.  Comparison of Clevidipine and Nicardipine for Acute Blood Pressure Reduction in Patients With Stroke , 2019, Journal of intensive care medicine.

[9]  G. Brophy,et al.  Clevidipine Versus Nicardipine for Acute Blood Pressure Reduction in a Neuroscience Intensive Care Population , 2017, Neurocritical Care.

[10]  P. Koudstaal,et al.  Cerebrovascular disease. , 2016, Handbook of clinical neurology.

[11]  C. Anderson,et al.  Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association , 2015, Stroke.

[12]  J. Tobias,et al.  A prospective, open-label trial of clevidipine for controlled hypotension during posterior spinal fusion. , 2015, The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG.

[13]  S. Aronson,et al.  A Cost Analysis of the Impact of a New Intravenous Antihypertensive in Managing Perioperative Blood Pressure during Cardiac Surgery , 2014, Hospital practice.

[14]  A. Mebazaa,et al.  Clevidipine in acute heart failure: Results of the A Study of Blood Pressure Control in Acute Heart Failure-A Pilot Study (PRONTO). , 2014, American heart journal.

[15]  L. Schultz,et al.  Clevidipine for acute hypertension in patients with subarachnoid hemorrhage: a pilot study , 2014, The International journal of neuroscience.

[16]  J. Broderick,et al.  Antihypertensives are administered selectively in emergency department patients with subarachnoid hemorrhage. , 2013, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[17]  Z. Gaciong,et al.  Blood Pressure Control and Primary Prevention of Stroke: Summary of the Recent Clinical Trial Data and Meta-Analyses , 2013, Current Hypertension Reports.

[18]  S. Bergese,et al.  Clevidipine Rapidly and Safely Reduces Blood Pressure in Acute Intracerebral Hemorrhage: The ACCELERATE Trial , 2013, Cerebrovascular Diseases.

[19]  K. Kario,et al.  Systolic Blood Pressure After Intravenous Antihypertensive Treatment and Clinical Outcomes in Hyperacute Intracerebral Hemorrhage: The Stroke Acute Management With Urgent Risk-Factor Assessment and Improvement-Intracerebral Hemorrhage Study , 2013, Stroke.

[20]  A. Gelb,et al.  Blood pressure management in stroke , 2012, Current opinion in anaesthesiology.

[21]  Paul Vespa,et al.  Guidelines for the Management of Aneurysmal Subarachnoid Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association , 2012, Stroke.

[22]  G. Rücker,et al.  Treatment-effect estimates adjusted for small-study effects via a limit meta-analysis. , 2011, Biostatistics.

[23]  M. Goldberg,et al.  Role of clevidipine butyrate in the treatment of acute hypertension in the critical care setting: a review , 2010, Vascular health and risk management.

[24]  Wolfgang Viechtbauer,et al.  Outlier and influence diagnostics for meta‐analysis , 2010, Research synthesis methods.

[25]  F. Veglio,et al.  Hypertension and cerebrovascular damage. , 2009, Atherosclerosis.

[26]  D. Moher,et al.  Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement , 2009, BMJ : British Medical Journal.

[27]  J. Varon,et al.  Clevidipine, an intravenous dihydropyridine calcium channel blocker, is safe and effective for the treatment of patients with acute severe hypertension. , 2009, Annals of Emergency Medicine.

[28]  M. Newman,et al.  The ECLIPSE Trials: Comparative Studies of Clevidipine to Nitroglycerin, Sodium Nitroprusside, and Nicardipine for Acute Hypertension Treatment in Cardiac Surgery Patients , 2008, Anesthesia and analgesia.

[29]  M. Newman,et al.  Treatment of Acute Postoperative Hypertension in Cardiac Surgery Patients: An Efficacy Study of Clevidipine Assessing Its Postoperative Antihypertensive Effect in Cardiac Surgery-2 (ESCAPE-2), a Randomized, Double-Blind, Placebo-Controlled Trial , 2008, Anesthesia and analgesia.

[30]  M. Newman,et al.  Clevidipine Effectively and Rapidly Controls Blood Pressure Preoperatively in Cardiac Surgery Patients: The Results of the Randomized, Placebo-Controlled Efficacy Study of Clevidipine Assessing Its Preoperative Antihypertensive Effect in Cardiac Surgery-1 , 2007, Anesthesia and analgesia.

[31]  A. Sutton,et al.  Comparison of two methods to detect publication bias in meta-analysis. , 2006, JAMA.

[32]  J. Saver.  Time Is Brain—Quantified , 2006, Stroke.

[33]  M. Volpe,et al.  Cerebrovascular Protection by New Antihyper tensive Drugs – Focus on RAS Blocking Agents in Stroke Prevention , 2006 .

[34]  Wolfgang Viechtbauer,et al.  Bias and Efficiency of Meta-Analytic Variance Estimators in the Random-Effects Model , 2005 .

[35]  Guido Knapp,et al.  Improved tests for a random effects meta‐regression with a single covariate , 2003, Statistics in medicine.

[36]  B M Psaty,et al.  Antihypertensive drug therapies and the risk of ischemic stroke. , 2001, Archives of internal medicine.

[37]  S Duval,et al.  Trim and Fill: A Simple Funnel‐Plot–Based Method of Testing and Adjusting for Publication Bias in Meta‐Analysis , 2000, Biometrics.

[38]  G. Smith,et al.  Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.

[39]  E. P. Richardson,et al.  Cerebrovascular Disease , 1997, Current opinion in neurology and neurosurgery.

[40]  S. Clissold,et al.  Nisoldipine. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of angina pectoris, hypertension and related cardiovascular disorders. , 1987, Drugs.

[41]  John Mandel,et al.  Consensus Values and Weighting Factors. , 1982, Journal of research of the National Bureau of Standards.

[42]  L. Hedges.  Distribution Theory for Glass's Estimator of Effect size and Related Estimators , 1981 .

[43]  W. Haenszel,et al.  Statistical aspects of the analysis of data from retrospective studies of disease. , 1959, Journal of the National Cancer Institute.